The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Medications for attention-deficit/hyperactivity disorder (ADHD) have some side effects that are common, while others are more ...

Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road.

Methylphenidate is a first-line treatment for ADHD and is associated with improved sleep. However, the effect of methylphenidate on sleep outcomes depends on multiple clinical and sociodemographic ...

To date, 13 trials 15 - 27 have evaluated methylphenidate versus placebo for the treatment of CRF, of which only five enrolled 100 or more participants. 15, 20, 22, 24, 27 The characteristics of the ...

Other forms of long-acting methylphenidate include the patch form (Daytrana) or Jornay, which is unique in that it is taken at night and released by the time you wake up (in theory).

Methylphenidate is also available in long-acting tablets (Concerta) and capsules (Ritalin LA). They are released into the body over the day.

More information: Xiangsheng Luo et al, Overactivated contextual visual perception and response to a single dose of methylphenidate in children with ADHD, European Archives of Psychiatry and ...

Specifically, methylphenidate is hypothesized to ameliorate ADHD symptoms by increasing dopamine levels in the nucleus accumbens (NAc), a hub for dopamine signaling.

At 6 months, methylphenidate 10 mg twice daily led to a larger decrease on the 12-point Neuropsychiatric Inventory (NPI) apathy scale compared with placebo, with a mean difference of -1.25 points ...